What is Aimovig
Aimovig is a migraine preventive medication that was recently approved by the FDA. It is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a molecule that is thought to play a role in migraine. By blocking CGRP, Aimovig may help to prevent migraine attacks.
Benefits of Aimovig
and Its Uses.
Aimovig is a novel drug that has been designed to prevent migraine attacks. It is a monoclonal antibody that has been specifically designed to block the activity of calcitonin gene-related peptide (CGRP), a protein that is involved in the initiation of migraine attacks.
Aimovig has been shown to be effective in preventing migraine attacks in both adults and children. It is well tolerated, and has been shown to be safe and effective in both short- and long-term use.
Aimovig is given as an injection under the skin (subcutaneous injection) once a month. It is available as a pre-filled syringe or as an auto-injector.
Side Effects and Dosage of Aimovig
Aimovig™ is a migraine preventive medication that was FDA-approved in May 2018. It is a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP), a molecule that is involved in the initiation and maintenance of migraine attacks.
Aimovig is given as a subcutaneous injection once a month. The recommended dosage is 70 mg.
The most common side effects of Aimovig are injection site reactions (pain, itching, swelling, redness, or bruising), headache, and nausea.
Aimovig can cause serious side effects, including:
– Severe allergic reactions. Get medical help right away if you have any symptoms of a severe allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
– Problems with your blood circulation. Get medical help right away if you have any of these